Du är här


Swedish Orphan Biovitrum AB (publ): Annette Clancy joins Sobi's Board of Directors

Annette Clancy joins Sobi's Board of Directors

Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General meeting (AGM) today
elected Annette Clancy to Sobi's Board of Directors. Ms. Clancy has over 30
years of experience in the Pharmaceutical and Biotechnology Industry, working
in a variety of roles in the US and UK. With Ms Clancy, Sobi's Board expands
to eight members with international experience in a wide variety of relevant
healthcare disciplines.

"I am delighted to welcome Annette to Sobi", said Bo Jesper Hansen, Chairman
of the Board at Sobi. "Annette's extensive experience from a variety of
senior R&D, commercial, and business development functions in the
pharmaceutical industry makes her a perfect addition to the Board. Annette's
skills, knowledge and experience will be invaluable to furthering the success
of Sobi."

Annette Clancy was born 1954 and has a BSc Hons Pharmacology, from Bath
University UK. She is Chairman as well as Non-Executive Director of the Board
in Genable Technologies and ObsEva SA. Ms. Clancy was Head of Transactions
and Alliance Management at GlaxoSmithKline (GSK) where she was responsible
for executing major transactions ranging from early drug discovery
partnerships, to global commercial alliances and Mergers and Acquisitions.
Since her retirement from GSK in 2008, Ms. Clancy has been appointed as
Non-Executive Board Director to Silence Therapeutics plc. (2008-2012) and
Clavis Pharma in Norway (2010-2013).

Ms. Clancy also currently serves as Senior European Advisor to the
Biopharmaceutical Team of Frazier Healthcare Ventures, for whom she provides
strategic advice on both new and existing investments. Annette Clancy does
not hold any shares or options in Sobi. She is independent in relation to the
company and its management and in relation to the company's principal

The ordinary Board members Adine Grate Axén, Matthew Gantz, Bo Jesper Hansen,
Lennart Johansson, Helena Saxon, Hans GCP Schikan and Hans Wigzell were
re-elected and Bo Jesper Hansen was re-elected chairman of the Board.


About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of
specialty and rare disease products for partner companies. Sobi is a pioneer
in biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
($334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available atwww.sobi.com.

For more information please contact

|Media relations Investor relations |
|Oskar Bosson, Jörgen Winroth, |
|Head of Communications Vice President, Head of Investor Relations |
|T: +46 70 410 71 80 T: +1 347-224-0819, +1 2125790506, +46 8 697 2135 |
|oskar.bosson@sobi.com jorgen.winroth@sobi.com |

The information was released for public distribution on May 8, 2014 at 18:30

Annette Clancy joins Sobi's Board of Directors


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.